BELRUX: Belumosudil With Ruxolitnib as Third Line Therapy for Chronic Graft Versus Host Disease (cGvHD) (clinicaltrials.gov) - Oct 3, 2026 - P2 | N=53 | Not yet recruiting | Sponsor: Dennis Kim | Trial completion date: Jul 2030 ➔ Nov 2030 | Initiation date: Jul 2026 ➔ Nov 2026 | Trial primary completion date: Jul 2029 ➔ Nov 2029
Trial completion date • Trial initiation date • Trial primary completion date • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology
|